CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Solving patients with rare diseases through programmatic reanalysis of genome-phenome data
Authors
Peter Hackman
Carles Hernández-Ferrer
+11 more
Mridul Johari
Leslie Matalonga
Davide Piscia
Marco Savarese
Solve-RD DITF-euroNMD
Solve-RD DITF-GENTURIS
Solve-RD DITF-ITHACA
Solve-RD DITF-RND
Solve-RD SNV-indel working group
the Solve-RD Consortia
Bjarne Udd
Publication date
1 September 2021
Publisher
Doi
Cite
Abstract
Publisher Copyright: © 2021, The Author(s).Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP’s Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics.Peer reviewe
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Helsingin yliopiston digitaalinen arkisto
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:helda.helsinki.fi:10138/34...
Last time updated on 28/02/2022